ARS Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ARS Pharmaceuticals, Inc.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The start-up, founded on science from the University of Pennsylvania, announced a $102m series A financing and the appointment of former Silverback CEO Laura Shawver as CEO.
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.
- Drug Delivery
- Other Names / Subsidiaries
- Silverback Therapeutics, Inc.